scholarly journals Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) is Underutilized in Myelodysplastic Syndrome (MDS): a Population-Based Canadian Province Experience

2011 ◽  
Vol 17 (2) ◽  
pp. S294 ◽  
Author(s):  
R. Kumar ◽  
E. Richardson ◽  
H. Khair ◽  
K. Paulson ◽  
D. Szwajcer ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Myelodysplastic Syndrome ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Population Based ◽  
Canadian Province ◽  
Hematopoietic Stem

scholarly journals Review of Stem-Cell Transplantation for Myelodysplastic Syndromes in Older Patients in the Context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome Emanating From the Centers for Medicare and Medicaid Services

2011 ◽  
Vol 29 (5) ◽  
pp. 566-572 ◽  
Author(s):  
Sergio A. Giralt ◽  
Mary Horowitz ◽  
Daniel Weisdorf ◽  
Corey Cutler
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Myelodysplastic Syndrome ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Myelodysplastic Syndromes ◽  
Older Patients ◽  
The United States ◽  
Hematopoietic Stem

Myelodysplastic syndromes (MDS) comprise a heterogeneous group of clonal hematopoietic stem-cell disorders that result in varying degrees of cytopenia and risk of transformation into acute leukemia. Allogeneic stem-cell transplantation (SCT) is the only known cure for this disease. The treatment is routinely used for younger patients, but only a minority of patients older than the age of 60 undergo this procedure. The overall MDS incidence is 3.3 per 100,000, but the incidence in patients older than age 70 is between 15 and 50 per 100,000. The median age at presentation is 76 years. Medicare-age patients 65 or older represent 80% of the total population receiving an MDS diagnosis. In the United States, one of the obstacles to SCT for older patients with MDS has been lack of third party reimbursement. On August 4, 2010, the Centers for Medicare and Medicaid Services released their Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Myelodysplastic Syndrome. This memo states: “Allogeneic HSCT for MDS is covered by Medicare only for beneficiaries with MDS participating in an approved clinical study that meets the criteria below…. ” In this review, we will summarize what is known regarding the role of allogeneic SCT in older patients as well as other elements that should be included within clinical trials that can provide the evidence necessary to demonstrate that allogeneic SCT should be a covered benefit for Medicare beneficiaries.

scholarly journals ARE WE READY TO INDICATE MYELODYSPLASTIC SYNDROME PATIENTS TO HEMATOPOIETIC STEM CELL TRANSPLANTATION BASED ON THEIR GENETIC STATUS?

JBMTCT ◽  
2020 ◽  
Vol 2 (1) ◽  
pp. 16-19
Author(s):  
Mair Pedro De Souza ◽  
Fernanda Leite Souza Franceschi ◽  
Fernando Barroso Duarte ◽  
Diego Coutinho ◽  
Beatrice Araujo Duarte ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Myelodysplastic Syndrome ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Hematopoietic Stem ◽  
Genetic Status

Mielodysplastic syndrome and hematopoietic stem cell transplantation based on genetic status.

Sign in / Sign up

Export Citation Format

Share Document